Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Two Step Approach to Allogeneic HSCT for High Risk Hematologic Malignancies
NCT03032783Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jan 2017
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in hematologic malignancy, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Overall Survival at 2 years. Started Jan 2017; status: completed.
02
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT03032783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03032783.